ASH MPN Spotlight

John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses studies investigating pacritinib for the treatment of myelofibrosis.

Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.

Treating patients with intermediate/high-risk myelofibrosis with the Janus kinase inhibitor ruxolitinib long-term demonstrated improved survival, pooled data from 2 randomized trials showed.

An international patient survey showed patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.